Articles related to CONTRACEPTION/BIRTH CONTROL

The FDA’s approval of Zurzuvae (zuranolone) as the first oral treatment for postpartum depression represents a significant advancement in patient care. Physicians are encouraged to explore this new option, considering both its proven efficacy and accompanying warnings, to provide more accessible care for those struggling with this serious condition.

This review delves into the neurological consequences of preterm birth, highlighting the particular brain impairments and developmental obstacles that survivors experience. Learn about the most recent advances in advanced neuroimaging and potential treatments to improve outcomes.

FDA’s approval of Opill, the first over-the-counter daily oral contraceptive, marks a major shift in contraceptive accessibility, opening new pathways in the prevention of unintended pregnancies.

As the FDA approves the first over-the-counter oral contraceptive, dental professionals must be cognizant of potential impacts on oral health and patient management.

Learn how pharmacists can dramatically improve access to reproductive health care, from removing obstacles to care to putting sexual and reproductive health services in place. Find out more about how you might contribute to this transition.

With a reported quarter of perinatal women in low and middle-income countries experiencing depression, the spotlight is on the global healthcare community to strategize and implement effective mental health interventions. This landmark study signals a pressing need to address this silent epidemic.